Source-grounded facts extracted from InspireMD, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
InspireMD, Inc. shareholders approved Ratification of Auditors at the 2026-06-03 meeting.
“Proposal No. 3 - Ratification of Auditors. The stockholders ratified the appointment of Kesselman & Kesselman, a member of PricewaterhouseCoopers International Limited, as the Company’s independent registered public accounting firm for the 2026 fiscal year. The votes were as follows: For Against Abstain 34,355,150 244,248 31,950”
InspireMD, Inc. shareholders approved Increase in Authorized Shares at the 2026-06-03 meeting.
“Proposal No. 2 – Increase in Authorized Shares. The stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the authorized number of shares of the Company’s common stock from 150,000,000 shares to 250,000,000 shares. The votes were as follows: For Against Withheld Broker Non-Votes 31,577,297 3,009,107 44,944 0”
InspireMD, Inc. shareholders approved Election of Directors at the 2026-06-03 meeting.
“Proposal No. 1 - Election of Directors. The stockholders re-elected Marvin Slosman, Raymond Cohen and Dan Dearen to serve on the board of directors of the Company, as Class 3 directors, for a term of three years or until their respective successor is elected and qualified. The votes were as follows: Director Name For Withheld Broker Non-Votes Marvin Slosman 25,086,284 1,728,950 7,816,114 Raymond Cohen 22,733,263 4,081,971 7,816,114 Dan Dearen 22,750,906 4,064,328 7,816,114”
Paul Stuka departed as Chair of the Board and Class I Director at InspireMD, Inc..
“On May 20, 2026, Mr. Paul Stuka notified InspireMD, Inc. (the “Company”) of his decision to not seek reelection as a Class I director of the Board of Directors of the Company (the “Board”) at the Company’s 2027 Annual Meeting of Stockholders (the “2027 Annual Meeting”) and to retire from the Board.”
InspireMD, Inc. reported first quarter ended March 31, 2026 results: revenue $3.4 million, net income $13.7 million, EPS $0.16 per basic and diluted share.
“expressly set forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- InspireMD Reports First Quarter 2026 Financial Results - Reports total Q1 2026 revenue of $3.4 million, representing year-over-year growth of 122% - - Received IDE approval from FDA to initiate the CGUARDIANS III clinical trial of its SwitchGuard neuro protection system for use in”
InspireMD, Inc. entered into Equity Distribution Agreement with BTIG, LLC valued at up to $75,000,000 (effective 2026-04-03).
“On April 3, 2026, InspireMD, Inc. (the “ Company ”) entered into an Equity Distribution Agreement (the “ Equity Distribution Agreement ”) with BTIG, LLC, as sales agent (“ BTIG ”), pursuant to which the Company may offer and sell (the “ Offering ”), from time to time, at its option, through or to BTIG shares of the Company’s common stock, $0.0001 par value per share (the “ Shares ”).”
InspireMD, Inc. reported the year ended December 31, 2025 results: revenue $9.0 million, net income $48.8 million or $0.76 per basic and diluted share. Guidance initiated.
“$9.2 million or $0.19 per basic and diluted share, for the same period in 2024. Financial Results for the Year Ended December 31, 2025 For the full year 2025, total revenue was $9.0 million, representing an increase of 28%, as compared to $7.0 million during the full year 2024. U.S. revenue for the full year 2025 was $1.4 million, representing the first two quarters”
InspireMD, Inc. reported the fourth quarter ended December 31, 2025 results: revenue $3.1 million, net income $11.8 million or $0.14 per basic and diluted share.
“of stroke, today announced financial and operating results for the fourth quarter and year ended December 31, 2025. Recent Business Highlights : ● Generated revenue of $3.1 million in the fourth quarter of 2025, up 62% year-over-year. ● Sustained strong commercial traction in the U.S. with the launch of CGuard Prime and continued growth in international”
Craig Shore was terminated as Chief Financial Officer at InspireMD, Inc..
“On the Effective Date, Mr. Lawless will succeed Craig Shore, whose employment as the Company’s Chief Financial Officer will be terminated simultaneous with Mr. Lawless’s appointment.”
Michael Lawless was appointed as Chief Financial Officer at InspireMD, Inc..
“On June 2, 2025, InspireMD, Inc. (the “ Company ”) appointed Michael Lawless as Chief Financial Officer of the Company, effective on or before June 30, 2025 (the “ Effective Date ”).”
Scott R. Ward was appointed as Class II member of the Board at InspireMD, Inc..
“On November 25, 2024, the board of directors of InspireMD, Inc. (the “Board” and the “Company”, respectively) appointed Mr. Scott R. Ward as a Class II member of the Board, effective as of that date, with a term expiring at the Company’s 2025 annual meeting of stockholders.”
InspireMD, Inc. reported first quarter ended March 31, 2024 results: revenue $1,511,000, net income $7,032,000, EPS $0.21 per basic and diluted share.
“For the first quarter of 2024, total revenue increased 22.0%, to $1,511,000, from $1,239,000 during the first quarter of 2023. This increase was predominantly driven by growth in existing markets . Gross profit for the first quarter of 2024 decreased by $81,000, or 21.6%, to $292,000, compared to a gross profit of $373,000 for the first quarter of 2023. This decrease resulted primarily from higher training costs of new hires to build capacity for anticipated increased volume requirements . Gross margin (gross profit as a percentage of revenue) decreased to 19.4% during the three months ended March 31, 2024, from 30.1% during the three months ended March 31, 2023. Total operating expenses for the first quarter of 2024 were $7,706,000, an increase of $2,952,000, or 62.1% compared to $4,754,000 for the first quarter of 2023. This increase was primarily due to higher share-based compensation resulting from the recognition of grants made during the second quarter of 2023 and the first quart”
InspireMD, Inc. reported financial results for the full-year ended December 31, 2023.
“InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuardTM Embolic Prevention System (EPS) for the treatment of carotid artery disease (CAD) and prevention of stroke, today announced financial and operating results for the fourth quarter and full-year ended December 31, 2023.”
InspireMD, Inc. reported the fourth quarter ended December 31, 2023 results: revenue $1,761,000.
“For the fourth quarter of 2023, total revenue increased 71.6%, to $1,761,000, from $1,026,000 during the fourth quarter of 2022.”
InspireMD, Inc. reported financial results for three and nine months ended September 30, 2023.
“On November 6, 2023, InspireMD, Inc. issued a press release announcing its financial and operating results and recent highlights for the three and nine months ended September 30, 2023.”
Amir Kohen changed role as Vice President of Finance and Human Resources at InspireMD, Inc..
“Mr. Kohen will resume his role as the Company’s Vice President of Finance and Human Resources, effective as of the date of Mr. Shore’s reappointment.”
Craig Shore was appointed as Chief Financial Officer, Secretary and Treasurer at InspireMD, Inc..
“On October 5, 2023, Mr. Shore was reappointed as the Chief Financial Officer, Secretary and Treasurer of the Company.”
InspireMD, Inc.: Amendment to Amended and Restated Certificate of Incorporation to eliminate or limit personal liability of certain officers for monetary damages for breach of fiduciary duty (effective 2023-09-13).
“At the Annual Meeting, the stockholders approved, among other things, an amendment to the Company’s Amended and Restated Certificate of Incorporation to eliminate or limit the personal liability of certain Company officers for monetary damages for breach of fiduciary duty as an officer, except to the extent such an exemption from liability or limitation thereof is not permitted by Delaware General Corporation Law (the “Amendment”).”
InspireMD, Inc. shareholders approved Ratification of appointment of Kesselman & Kesselman as independent registered public accounting firm for 2023 at the 2023-09-13 meeting.
“The stockholders ratified the appointment of Kesselman & Kesselman, a member of PricewaterhouseCoopers International Limited, as the Company's independent registered public accounting firm for the 2023 fiscal year. The votes were as follows: For Against Abstain 16,644,594 29,427 43,212”
InspireMD, Inc. shareholders approved Amendment to Amended and Restated Certificate of Incorporation to limit liability of officers at the 2023-09-13 meeting.
“The stockholders approved an amendment to the Company's Amended and Restated Certificate of Incorporation to limit the liability of certain officers of the Company as permitted by recent amendments to Delaware law. The votes were as follows: For Against Abstain Broker Non-Votes 12,643,674 1,940,907 10,878 2,121,774”
InspireMD, Inc. shareholders approved Potential issuance of shares in the private placement offering (change of control) at the 2023-09-13 meeting.
“The stockholders approved the potential issuance of shares in the Private Placement Offering (as defined in the Proxy Statement"), which would result in a "change of control" of the Company under the applicable rules of The Nasdaq Stock Market LLC. The votes were as follows: For Against Abstain Broker Non-Votes 4,267,740 111,880 10,818 2,121,7 74”
InspireMD, Inc. shareholders approved Election of three Class 3 directors at the 2023-09-13 meeting.
“The stockholders re-elected Marvin Slosman, Thomas J. Kester and Kathryn Arnold to serve on the Board of Directors, as Class 3 directors, for a term of three years or until his or her successor is elected and qualified. The votes were as follows: Director Name For Withheld Broker Non-Votes Marvin Slosman 14,417,531 177,928 2,121,7 74 Thomas J. Kester 14,420,292 175,167 2,121,7 74 Kathryn Arnold 14,415,373 180,086 2,121,774”
InspireMD, Inc. reported the six months ended June 30, 2023 results: revenue $2,888,000, net income $9,333,000, EPS $0.64 per basic and diluted share.
“after deducting transaction expenses. Financial Results for the Six Months ended June 30, 2023 For the six months ended June 30, 2023, revenue increased by $174,000, or 6.4%, to $2,888,000, from $2,714,000 during the six months ended June 30, 2022. This increase was predominantly driven by a 8.3% increase in sales volume of CGuard EPS from $2,666,000 during the”
InspireMD, Inc. reported the three months ended June 30, 2023 results: revenue $1,649,000, net income $5,077,000, EPS $0.24 per basic and diluted share.
“performed with its CGuard Prime CAS stent delivery platform as part of C-Guardians trial enrollment. ● Generated record CGuard revenue for the second quarter 2023 of $1,649,000, a 9.6 % increase over the same period in 2022 and a 33% increase over the first quarter of 2023. ● Sold 2,804 CGuard EPS stent systems in the second quarter of 2023, as compared”
Amir Kohen was appointed as interim Chief Financial Officer at InspireMD, Inc..
“On July 20, 2023, the Board of Directors of InspireMD, Inc. (the “Company”) appointed Amir Kohen, the Company’s Vice President of Finance and Human Resources, to serve as of interim Chief Financial Officer, Secretary and Treasurer during the time that Craig Shore is out on medical leave.”
InspireMD, Inc. reported first quarter ended March 31, 2023 results: revenue $1,239,000.
“For the three months ended March 31, 2023, revenue increased by $56,000, or 4.7%, to $1,239,000, from $1,183,000 during the three months ended March 31, 2022.”
InspireMD, Inc. entered into Purchase Agreement valued at approximately $42.2 million (effective 2023-05-12).
“On May 12, 2023, InspireMD, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”)”
InspireMD, Inc. reported the year ended December 31, 2022 results: revenue $5,171,000.
“For the twelve months ended December 31, 2022, total revenue increased by $676,000, or 15.0%, to $5,171,000, from $4,495,000 during the twelve months ended December 31, 2021.”
InspireMD, Inc. reported fourth quarter ended December 31, 2022 results: revenue $1,026,000, net income Net loss for the fourth quarter of 2022 totaled $4,845,000, or $0.60 per basic and diluted share, EPS $0.60 per basic and diluted share.
“and operating results for the fourth quarter ended December 31, 2022. Fourth Quarter 2022 and Recent Developments : ● Generated CGuard revenues for the fourth quarter 2022 of $1,026,000, a 20.6% decrease from $1,291,000 for the fourth quarter of 2021. The decrease was caused by reduced shipments due to the temporary expiration of the Company’s CE Mark for the”
Andrea Tommasoli changed role as Chief Operating Officer at InspireMD, Inc..
“On March 19, 2023, InspireMD, Inc. (the “Company”), announced that its Board of Directors (the “Board”) promoted Andrea Tommasoli to Chief Operating Officer of the Company, effective as of March 19, 2023.”
InspireMD, Inc. reported financial results for three and nine months ended September 30, 2022.
“On November 8, 2022, InspireMD, Inc. issued a press release announcing its financial and operating results and recent highlights for the three and nine months ended September 30, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.